A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304

Trial Profile

A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Adverse reactions
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 20 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top